Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05138003
Other study ID # 2021/051
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 1, 2021
Est. completion date October 1, 2023

Study information

Verified date October 2023
Source Jessa Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will evaluate myocardial inflammation in cyclists after high intense and sustained exercise. Our hypothesis is that strenuous exercise in recreational cyclists may be associated with myocardial inflammation. Myocardial fibrosis in asymptomatic athletes is associated with life-threatening arrhythmic events and sudden death. Although myocarditis seems to be the most likely underlying cause, it remains unclear if strenuous and sustained physical exercise can cause myocardial inflammation with development of myocyte necrosis and possibly myocardial fibrosis in athletes. Nineteen recreational cyclists performing "L'ETAPE DU TOUR (EDT) de France" a cycling ride (175 km, 3600 m of positive altitude difference) on July 4 2021 will be included in this study. Each participant will complete a detailed questionnaire detailing their training history. All participants will have exercise testing approximately 1 week before the EDT stage to set aerobic and anaerobic gas exchange thresholds, as well as VO2max. In part 2 of the study cardiac MRI will be performed at rest before the EDT cycling ride completion. An ECG registration using a RootiRx will be realized during and up to 6 hours after the cycling ride. An echocardiography and cardiac MRI will be repeated in each cyclist between 3 and 6 hours after EDT cycling ride completion. A blood sample will be obtained at that time after the ride. This time point is chosen based on the highest troponin release that 3 to 6 hours post-exercise would allow a sufficient amount of time for inflammation to develop and be detectable, corresponding with the time when cardiac Troponin T is typically detectable and representing the liberation of enzymes from damaged myocytes. Finally, a third cardiac MRI will be repeated 24 hours after start of the cycling ride to verify the evolution of possible inflammation over this time period.


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date October 1, 2023
Est. primary completion date July 5, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Recreational cyclists performing the 'étape du tour (EDT) de France 2021 ride Exclusion Criteria: - presence of pre-existing cardiovascular or pulmonary diseases, hypertension, diabetes, peripheral vascular diseases, any inflammatory or auto-immune diseases, active SARS-CoV-2 infection and the intake of anti-inflammatory drugs.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
cardiac MRI
T1 and T2 relaxation times will be evaluated on basal and mid-cavity SA maps; a single ROI measurement in the septum will be manually drawn sufficiently far from tissue interfaces to avoid the impact of susceptibility artifacts from adjacent tissues. The differences in T1 and T2 relaxation times between rest and post-exercise will be analyzed. Cardiac ventricular volumes, function and LV mass will also be quantified.
Echocardiography
Measurements of mass, volumes and function will be obtained of both the left and right ventricles enabling comparisons with cardiac MRI and traditional echo measures.
RootiRx for the ECG monitoring during the cycling ride
The final report will include the amount of recorded beats, the average heart rate, the maximum and minimum heart rate, the amount of cardiac pauses defined as an interruption in the ventricular rate > 2 seconds. Reported atrial events include atrial ectopic beats and supraventricular tachycardia and ventricular events include ventricular ectopic beats, doublets, triplets, bigeminy, trigeminy and ventricular tachycardia.
Blood sample
Blood sample will be performed 3 to 6 hours after the stage to analyze high-sensitivity cardiac Troponin T (high-sensitivity) levels, Creatine Phosphokinase (CPK) to eliminate the hypothesis of Troponin elevation induced by rhabdomyolysis and C-reactive Protein to corroborate the inflammatory aspect if there is any.

Locations

Country Name City State
Belgium Jessa Hospital Hasselt
France Centre Hospitalier Universitaire de Nice Nice

Sponsors (2)

Lead Sponsor Collaborator
Jessa Hospital Centre Hospitalier Universitaire de Nice

Countries where clinical trial is conducted

Belgium,  France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Myocardial inflammation will be evaluated by T1/T2 mapping cardiac MRI in cyclists after a strenuous exercise T1 and T2 relaxation time will be measured on cardiac MRI in cyclists before and 3 to 6 hours after a high intense and sustained exercise to assess exercise-induced myocardial inflammation 12 months after study
See also
  Status Clinical Trial Phase
Completed NCT03607071 - Outcome of Steroid Therapy for Myocardial Inflammation in Scleroderma Phase 2
Completed NCT04322630 - Mer-TK in Human Cardiac Cells
Completed NCT03776682 - Myocardial Inflammation in Rheumatoid Arthritis: A Descriptive Study
Completed NCT04940650 - COUREUR Study Myocardial Inflammation in Cyclist Part 1 N/A
Terminated NCT03619876 - Effects of Abatacept on Myocarditis in Rheumatoid Arthritis Phase 4
Completed NCT03782259 - Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2 Phase 4
Recruiting NCT03525639 - CMR Evaluation of Myocardial Inflammation Persistence After Acute Myocarditis: Prognostic Relevance N/A
Terminated NCT03103490 - 18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation Phase 2
Completed NCT04437927 - Impact of 100mL Lipid Emulsion for Intravenous for Suppression of Myocardial Glucose Metabolism in 18F-FDG PET/CT
Recruiting NCT05519735 - Lymphatic Organs and Myocardium After Myocardial Infarction N/A